




47-1647  
PATENT  
Case Docket No. GNE.3230R1C160  
Date: December 20, 2004  
Page 1  
*listing*

In re application of : Goddard, et al. (as amended)  
App. No. : 10/063,732  
Filed : May 8, 2002  
For : A NUCLEIC ACID  
OVEREXPRESSED IN  
ESOPHAGEAL AND LUNG  
TUMOR, AND  
UNDEREXPRESSED IN  
KIDNEY TUMOR AND  
MELANOMA (as amended)  
Examiner : Seharaseyon, J.  
Art Unit : 1647

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

December 20, 2004

(Date)

  
AnneMarie Kaiser, Reg. No. 37,649

**COMMISSIONER FOR PATENTS**  
**P.O. Box 1450**  
**Alexandria, VA 22313-1450**

Sir:

Transmitted herewith is an amendment in the above-identified application.

The fee has been calculated as shown below:

**CLAIMS AS FILED**

	<b>CLAIMS REMAINING AFTER AMENDMENT</b>		<b>HIGHEST NO. PREVIOUSLY PAID FOR</b>	<b>PRESENT EXTRA</b>	<b>RATE</b>	<b>ADDITIONAL FEE</b>
Total Claims	19	—	20	= 0 ×	\$50	= \$0
Independent Claims	3	—	3	= 0 ×	\$200	= \$0
					\$360	= \$0
Time Extension Fee						\$0
				<b>TOTAL ADDITIONAL FEE FOR THIS AMENDMENT</b>		<b>\$0</b>

(X) A Response to Notice to Comply, Copy of Notice to Comply, and Sequence Listing are enclosed.


(X) Exhibits 1-10 are enclosed.

01/03/2005 BABRAHAI 00000089 10063732

01 FC:1464

130.00 DP

- (X) Return prepaid postcard.
- (X) A check in the amount of \$130 is enclosed for the deletion of inventors.
- (X) Please charge any additional fees, including any fees for additional extension of time, or credit overpayment to Deposit Account No. 11-1410.
- (X) Please use Customer No. 30,313 for the correspondence address.



AnneMarie Kaiser  
Registration No. 37,649  
Attorney of Record  
Customer No. 30,313  
(619) 235-8550

**COPY****Notice to Comply**Application No.  
10/063 732

Applicant(s)

Eaton et al.

Examiner  
J. SchowalekArt Unit  
(642)**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS  
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE  
DISCLOSURES**

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).

2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).

3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).

4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."

5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).

6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).

7. Other:

**Applicant Must Provide:**

An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".

An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.

A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216 or (703) 308-2923

For CRF Submission Help, call (703) 308-4212 or 308-2923

PatentIn Software Program Support

Technical Assistance.....703-287-0200

To Purchase PatentIn Software.....703-306-2600

**PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY**

